STRATA Skin Sciences Q1 revenue $6.8M (-11% YoY); net loss widens to $3.4M

STRATA Skin Sciences, Inc.

2024-Q1 EPS reported -$0.10 revenue$6,754,000

Revenue $6.8M vs $7.6M YoY; global recurring revenue $4.7M (-10% YoY).
Net loss $3.4M ($0.10 per share) vs $2.8M ($0.08) in Q1 2023.
Gross margin fell to 46% from 58% YoY; operating expenses cut 14% to $6.0M.
Domestic installed base: 907 XTRAC (down from 923 in Dec 2023); 104 TheraClear X (up from 92).
Amended credit agreement with MidCap Financial; renewed 3-year exclusive distributor deals in China and Japan.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STRATA Skin Sciences, Inc. reported the first fiscal quarter ended March 31, 2024 results: revenue $6.8 million, net income Net loss of $3.4 million, EPS net loss of $0.10 per basic and diluted common share.

Period: the first fiscal quarter ended March 31, 2024
Revenue: $6.8 million
Net income: Net loss of $3.4 million
EPS: net loss of $0.10 per basic and diluted common share
Result: reported results

Exact text from the filing

announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights • Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the first quarter of 2023 o Global net recurring revenue in the first quarter of 2024 was $4.7 million (-10% YOY) vs. $5.2 million in the first

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-026254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.